News | May 22, 2022
Glenmark Pharma gets observations from USFDA for its Goa and Monroe facilities
A total of five observations for Goa and 17 for Monroe
A total of five observations for Goa and 17 for Monroe
The company continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Key takeaways of Q3FY22 quarter & conference call highlights
The company reports revenue growth of 26% and PAT growth of 21% YoY
Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina
This marks Glenmark's first synthetic decapeptide injectable approval
Subscribe To Our Newsletter & Stay Updated
